Oramed Pharmaceuticals Inc. Forecast, price target & analysts
Oramed Pharmaceuticals Inc. Target price 2025 - Analyst rating & recommendation
Oramed Pharmaceuticals Inc. Classifications & Recommendation:
Oramed Pharmaceuticals Inc. Price Target
| Target Price | $3.32 |
| Price | $2.27 |
| Potential |
46.04%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Oramed Pharmaceuticals Inc. 2026 .
The average Oramed Pharmaceuticals Inc. target price is $3.32.
This is
46.04%
register free of charge
$3.41
50.33%
register free of charge
$3.28
44.60%
register free of charge
|
|
| A rating was issued by 6 analysts: 0 Analysts recommend Oramed Pharmaceuticals Inc. to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oramed Pharmaceuticals Inc. stock has an average upside potential 2026 of
46.04%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 2.04 |
| 100.00% |
3 Analysts have issued a sales forecast Oramed Pharmaceuticals Inc. 2025 . The average Oramed Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $0.0 | 100.00% |
|---|
3 Oramed Pharmaceuticals Inc. Analysts have issued a net profit forecast 2025. The average Oramed Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $-19.1m | 444.67% |
|---|---|---|
| 2025 |
$-14.2m
25.66%
Unlock
|
|
Net Margin
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.47 | -0.35 |
| 435.71% | 25.53% | |
| P/E | negative | |
| EV/Sales | negative |
3 Analysts have issued a Oramed Pharmaceuticals Inc. forecast for earnings per share. The average Oramed Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $-0.47 | 435.71% |
|---|---|---|
| 2025 |
$-0.35
25.53%
Unlock
|
|
P/E ratio
| Current | -4.05 | 117.03% |
|---|---|---|
| 2025 |
-6.55
61.58%
Unlock
|
|
Based on analysts' sales estimates for 2025, the Oramed Pharmaceuticals Inc. stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -2.43 | |
|---|---|---|
| 2025 |
-2.38
1.96%
Unlock
|
|
P/S ratio
| Current | ||
|---|---|---|
| 2025 |
45.63
1.96%
Unlock
|
|
Oramed Pharmaceuticals Inc....
Current Oramed Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
